Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4245288 | 0.84 | DEGS1 (0.51) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL4246914 | 0.84 | MAPT (0.43) | LMNAMEN1KMT2ASMN1; SMN2POLB | |
| SCHEMBL4237397 | 0.82 | MAPT (0.46) | LMNAMEN1KMT2AHTTSMN1; SMN2 | |
| SCHEMBL4246968 | 0.81 | EPHX1 (0.48) | LMNAMEN1KMT2AHTTSMN1; SMN2 | |
| SCHEMBL4250686 | 0.80 | KMT2A (0.44) | LMNAMEN1KMT2AHTTSMN1; SMN2 | |
| SCHEMBL13598079 | 0.80 | RXFP1 (0.48) | RXFP1LMNAMEN1KMT2AHTT | |
| SCHEMBL4246135 | 0.79 | ALDH1A1 (0.52) | LMNAMEN1KMT2ASMN1; SMN2POLB | |
| SCHEMBL4421045 | 0.78 | RXFP1 (0.46) | RXFP1MEN1KMT2ASMN1; SMN2POLB | |
| SCHEMBL4421044 | 0.78 | RXFP1 (0.46) | RXFP1MEN1KMT2ASMN1; SMN2POLB | |
| SCHEMBL13743509 | 0.78 | NPC1 (0.51) | RXFP1SMN1; SMN2NPC1RAB9APTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203694-A1 | INHIBITORS OF UNDECAPRENYL PYROPHOSPHATE SYNTHASE | HURLEY TIMOTHY BRIAN | 2009-08-13 | — | — | US | disclosed |
| US-20090203694-A1 | INHIBITORS OF UNDECAPRENYL PYROPHOSPHATE SYNTHASE | HURLEY TIMOTHY BRIAN | 2009-08-13 | — | — | US | disclosed |
| US-20090203694-A1 | INHIBITORS OF UNDECAPRENYL PYROPHOSPHATE SYNTHASE | HURLEY TIMOTHY BRIAN | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203694-A1 | INHIBITORS OF UNDECAPRENYL PYROPHOSPHATE SYNTHASE | FDPS, UMPS, GGPS1 | RXFP1 4700/4885LMNA 2709/4885MEN1 2345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.